Blood cancers

MTX neurotoxicity risk low in ALL; don’t stop treatment

Clinicians managing children with ALL or or lymphoblastic lymphoma should not cease intrathecal MTX therapy after a first episode of MTX neurotoxicity, especially when it occurs early in therapy. An Australian study of 1251 children from six paediatric oncology centres found 7.6% of the cohort fulfilled the criteria for MTX neurotoxicity. MTX neurotoxicity included symptoms ...

Already a member?

Login to keep reading.

© 2021 the limbic